Peptron, Inc. engages in the development of peptide-based medicines and novel drugs. Its products include medicines for prostate cancer, hyperpituitarism, diabetes, degenerative neuronal disease, and obesity, peptide materials, and cosmetics. The company was founded on November 21, 1997 and is headquartered in Daejeon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company